Prestige Consumer Healthcare Reports $1.09 Billion in Revenue, 4.3% Decline for Fiscal Year Ending March 31, 2026

Prestige Consumer Healthcare Inc. reported total revenues of $1,088.7 million for the fiscal year ending March 31, 2026, a decrease of 4.3% from $1,137.8 million in the previous year. The decline was primarily driven by a significant drop in sales within the Eye & Ear Care category, particularly affecting the Clear Eyes brand, which faced supply constraints. The North American OTC Healthcare segment, which constitutes 83.9% of total revenues, saw a revenue decrease of 4.8%, while the International OTC Healthcare segment experienced a smaller decline of 1.5%.

The company's gross profit also fell, decreasing by $38.9 million, or 6.1%, to $595.6 million, resulting in a gross profit margin of 54.7%, down from 55.8% in 2025. This decline was attributed to increased costs associated with the acquisition of a Canadian manufacturing facility and inflationary pressures affecting various product categories. The contribution margin, which reflects gross profit less advertising and marketing expenses, decreased to $446.8 million, or 41.0% of total revenues, compared to 42.1% in the prior year.

Strategically, Prestige Consumer Healthcare has been active in acquisitions, completing the purchase of Pillar5 Pharma Inc. in December 2025, a move aimed at enhancing its manufacturing capabilities for sterile ophthalmic products. Additionally, the company has entered into a definitive agreement to acquire a portfolio of over-the-counter brands from Foundation Consumer Brands, expected to close in the first half of fiscal 2027. These acquisitions are part of the company's broader strategy to expand its product offerings and market presence.

As of March 31, 2026, Prestige Consumer Healthcare employed approximately 890 individuals, with a workforce that is 52% female and 48% male. The company continues to focus on expanding its international presence, with international sales accounting for 16.1% of total revenues, up from 14.8% in 2024. The company anticipates that its international revenues will continue to grow as it seeks to expand its brand distribution in various global markets.

Looking ahead, Prestige Consumer Healthcare faces challenges from ongoing economic volatility, including inflation and supply chain disruptions, which could impact consumer demand and operational costs. The company remains committed to leveraging its established brand portfolio and distribution network to navigate these challenges while pursuing growth through strategic acquisitions and product innovation.